Rapid phase II metabolism of belinostat via glucuronidation, primarily by the UGT1A1 enzyme, is the likely source of the short half-life of this drug, resulting in limited activity in solid tumors such as colon cancer [13]. Here, UGT1A1 is linked to malignant colon neoplasm.